Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Human gene therapy and congress.

R M Cook-Deegan1

  • 1Kennedy Institute of Ethics, Georgetown University.

Human Gene Therapy
|January 1, 1990
PubMed
Summary

Congressional debates on human gene therapy in the 1980s focused on germ-line interventions. Despite significant discussion, Congress did not pass laws, acting primarily as a forum for ethical and scientific discourse.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Protecting the vulnerable in brain research.

Cerebrum : the Dana forum on brain science·2005
Same author

Privacy, families, and human subject protections: some lessons from pedigree research.

The Journal of continuing education in the health professions·2002
Same author

Intellectual property. Patents, secrecy, and DNA.

Science (New York, N.Y.)·2001
Same author

Inner sanctum.

Science (New York, N.Y.)·1999
Same author

Alzheimer testing at Silver Years.

Cambridge quarterly of healthcare ethics : CQ : the international journal of healthcare ethics committees·1998
Same author

Insulin gene patent litigation.

Science (New York, N.Y.)·1998

Area of Science:

  • Biomedical Ethics
  • Human Genetics
  • Gene Therapy Research

Background:

  • Congressional debate on human gene therapy intensified in the 1980s.
  • Concerns regarding germ-line gene therapy, fueled by public interest groups and religious figures, drove early discussions.
  • Specific events, such as Martin Cline's 1980 gene therapy misadventures, heightened congressional scrutiny.

Purpose of the Study:

  • To analyze the nature and impact of congressional debates on human gene therapy during the 1980s.
  • To examine the legislative and ethical considerations surrounding gene therapy research and clinical trials.
  • To understand Congress's role in shaping public discourse on genetic interventions.

Main Methods:

  • Historical analysis of congressional records and hearings related to gene therapy.
Keywords:
Analytical ApproachBiomedical Ethics Advisory CommitteeBiomedical Ethics BoardGenetics and ReproductionLegal ApproachNational Institutes of HealthOffice of Technology AssessmentPresident's Commission for the Study of Ethical ProblemsRecombinant DNA Advisory CommitteeSplicing LifeU.S. Congress

Related Experiment Videos

  • Review of policy reports and legislative initiatives concerning biomedical ethics.
  • Examination of public and expert commentary on germ-line versus somatic gene therapy.

    • Main Results:

    • Congressional interest in gene therapy was significant, particularly concerning germ-line applications.
    • Key figures like Congressman Albert Gore, Jr. played a role in initiating hearings and requesting reports.
    • Despite extensive debate, Congress did not enact substantive legislation to regulate gene therapy research or trials.
    • An attempt to re-establish a federal bioethics commission through the Biomedical Ethics Board and Advisory Committee proved unsuccessful.

    Conclusions:

    • Congress served as a national platform for debating the ethical and scientific implications of human gene therapy.
    • Future decisions regarding germ-line gene therapy trials may depend on perceived safety and potential clinical benefits.
    • The lack of legislative action suggests a cautious, observational approach by Congress during this formative period.